Navigation Links
New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced
Date:9/25/2007

CARMEL, Ind., Sept. 25 /PRNewswire/ -- Diabco Life Sciences, LLC, an Indiana based company, has introduced a new clinically tested nutraceutical product for consumers concerned about the growing health risks associated with diabetes. This new product, Diabatrol, is a nutrient dense, fiber and antioxidant-rich dietary supplement that has been scientifically proven to stabilize blood sugar spiking and reduce insulin resistance, two conditions that most often lead to Type II diabetes.

Diabetes Risk Rising in the U.S.

According to the American Diabetes Association and the Centers for Disease Control and Prevention, Americans are increasingly at risk for diabetes. Currently, an estimated 107 million individuals in the U.S. are at risk of diabetes or pre-diabetes. Diabetes is a complex disease that impacts many vital functions and organs in the human body. Diabetes can cause vascular and nerve damage, heart disease, increased risk for kidney failure, and blindness. Diabetes experts advise that preventative action, early detection and aggressive management of diabetes can greatly improve the chances for a long and healthy life without significant health complications.

Diabatrol's Role in Reducing Risk

By reducing insulin resistance, Diabatrol works to allow the body to properly utilize insulin and stabilize blood glucose imbalances naturally, thereby helping to reduce the health risks associated with diabetes. Diabatrol's active ingredients not only help promote healthy glucose metabolism, but also help reduce oxidative stress and insulin resistance, two key concerns for diabetics and pre-diabetics.

Diabatrol is a nutraceutical with all natural active ingredients, not a prescription pharmaceutical. Diabatrol is a fortified whole grain derivative that provides a broad nutritional approach to diabetes management. All active nutritional components in Diabatrol have been clinically tested and documented to be beneficial for Type II diabetics. Diabatrol is hypoallergenic, gluten free, low glycemic and contains more than 80 natural antioxidants. Packaged in easy to use single-serving packets, Diabatrol provides a proactive nutritional approach to blood glucose management that can be easily incorporated into a total healthy lifestyle and diabetes wellness program.

Clinical testing of Diabatrol's active ingredients yielded the following results: In a 60-day double-blind randomized trial, Type II diabetes test subjects taking Diabatrol realized a 32.9 percent (52 points) reduction in fasting blood glucose levels and an eight percent reduction in LDL (so-called "bad cholesterol") levels. These clinical tests were peer reviewed and published in the Journal of Nutritional Biochemistry and are more fully documented on the Diabco Life Sciences website at http://www.healthydiabetic.com.

The term nutraceuticals refers to foods that have proven medical or health benefits to help mitigate certain diseases. Diabatrol is among the first nutraceuticals that conform to the new guidelines established under the U.S. Dietary Supplements, Health and Education Act (DSHEA), which is overseen by the U.S. Food and Drug Administration. DSHEA was established by the federal government to regulate the nutritional supplements industry and provide consumers with reliable guidelines for evaluating claims made by makers of such products.

About Diabco Life Sciences, LLC

Diabco Life Sciences, LLC (Diabco) was established in 2003 to focus on diabetes and product research. Diabco's mission is to provide effective nutraceutical products for consumers seeking performance-proven natural alternatives to help manage their blood glucose metabolism and to reduce the health risks associated with Type II diabetes and pre-diabetes. Nutraceuticals are nutrient dense functional foods, "medical foods" by definition that have been tested and proven to help mitigate certain health risks. More information about Diabco can be found at http://www.healthydiabetic.com or by writing to Diabco Life Sciences, 484 East Carmel Drive, #204, Carmel, Indiana, 46032.


'/>"/>
SOURCE Diabco Life Sciences, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Drug stabilizes cancer growth
2. Recommendations for Treatment of Blood Pressue
3. Blood Cells Capable of Regenerating Liver
4. Infant receives first bloodless liver transplant
5. Spouses and other partners lower blood pressure says new research
6. H2O - a cure for low blood pressure
7. Uncontrolled blood pressure
8. Weight and Blood Pressure
9. Grandmother’s diet in pregnancy can affect grandchildren’s blood sugr
10. Early diagnosis for autism from blood tests may be possible
11. Antibiotic from crab blood indentified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: